Latest Biotech News

ETFs (Exchange-Traded Funds) which can be traded like stock at any time during market hours, have low expense ratios, have less risk than individual stocks, do not have some of the tax disadvantages of a regular mutual fund, do not pool investor capital, and are constructed so they are far less susceptible than “standard” mutual funds to... 

This is a world that is fast developing and progressing. This progress needs to be matched and kept in pace by developments in the world of pharmaceuticals too. There are many educational institutions that offer specialized pharmaceutical courses for tracking, testing and propagating the advancements that are occurring at a breakneck speed in the dynamic... 

Hong Kong is one of the top international business, trade and financial hub drive of China.  Building on its traditional free market economic policy, Hong Kong has developed into a modern, vibrant and cosmopolitan services economy, underpinning the role of the city as a global business platform.   The Hong Kong government will continue to pursue closer... 

The chemicals manufactured by Canada Chemicals (Delta Bio Research Chemicals) are the mother of all chemicals because they are designed for use in scientific research investigation. Yes, the company is itself research-based specializing in synthesizing organic molecules for pharmaceuticals and drugs, and is known for fine research chemical products... 

The stock market stalled today with the Senate testimony of Federal Reserve Chairman Ben Bernanke and Secretary Treasurer Geithner as investors looked for positive clues about the economy and the effectiveness of the stimulus and banking plans. We didn’t get the big down day with high volume that we wanted to give us the high odds bottom... 

Rowan Gibson is a global business strategist, a bestselling author and an expert on radical innovation. He is also one of world’s most in-demand business speakers. Rowan’s books have been translated into over 20 languages. His new book Innovation to the Core (co-authored with Peter Skarzynski) was published in March 2008 by Harvard Business...